Table of Contents
ISRN Hypertension
Volume 2013 (2013), Article ID 780702, 9 pages
http://dx.doi.org/10.5402/2013/780702
Review Article

Meta-Analysis of the Hemodynamic Properties of Antihypertensive Medications

1Department of Medicine, School of Medicine, University of South Carolina, One Richland Medical Park, Suite 300, Columbia, SC 29203, USA
2Department of Family Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
3University Hospitals Medical Practice, Berea Health Center, 201 Front Street, Berea, OH 44017, USA
4Pakistan Atomic Energy Hospital, Islamabad, Pakistan
5Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH 44106, USA

Received 16 August 2012; Accepted 6 September 2012

Academic Editors: C. Saha and B. Waeber

Copyright © 2013 Imran Hasan Iftikhar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Hodges and E. L. Lehmann, Basic Concepts of Probability and Statistics, Holden-Day, San Francisco, Calif, USA, 2nd edition, 1970.
  2. S. N. Hunyor, A. J. Zweifler, L. Hansson, M. A. Schork, and C. Ellis, “Effect of high dose spironolactone and chlorthalidone in essential hypertension: relation to plasma renin activity and plasma volume,” Australian and New Zealand Journal of Medicine, vol. 5, no. 1, pp. 17–24, 1975. View at Google Scholar · View at Scopus
  3. P. Lund-Johansen, “Hemodynamic changes in long-term diuretic therapy of essential hypertension. A comparative study of chlorthalidone, polythiazide and hydrochlorothiazide,” Acta Medica Scandinavica, vol. 187, no. 6, pp. 509–518, 1970. View at Google Scholar · View at Scopus
  4. S. Shah, I. Khatri, and E. D. Freis, “Mechanism of antihypertensive effect of thiazide diuretics,” American Heart Journal, vol. 95, no. 5, pp. 611–618, 1978. View at Google Scholar · View at Scopus
  5. R. J. Solomon, N. Stillman, and M. S. Weinberg, “Thiazide induced hypotension: the role of plasma volume reduction and the urinary kallikrein system,” Advances in Experimental Medicine and Biology, vol. 198, pp. 243–251, 1986. View at Google Scholar · View at Scopus
  6. P. van Brummelen and M. A. D. H. Schalekamp, “Body fluid volumes and response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension,” Acta Medica Scandinavica, vol. 207, no. 4, pp. 259–264, 1980. View at Google Scholar · View at Scopus
  7. P. van Brummelen, A. J. Man In 'T Veld, and M. A. D. H. Schalekamp, “Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders,” Clinical Pharmacology and Therapeutics, vol. 27, no. 3, pp. 328–336, 1980. View at Google Scholar · View at Scopus
  8. S. Vardan, M. H. Dunsky, N. E. Hill et al., “Effect of one year of thiazide therapy on plasma volume, renin, aldosterone, lipids and urinary metanephrines in systolic hypertension of elderly patients,” American Journal of Cardiology, vol. 60, no. 4, pp. 388–390, 1987. View at Google Scholar · View at Scopus
  9. S. Vardan, S. Mookherjee, R. Warner, and H. Smulyan, “Systolic hypertension in the elderly. Hemodynamic response to long-term thiazide diuretic therapy and its side effects,” The Journal of the American Medical Association, vol. 250, no. 20, pp. 2807–2813, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Freier, G. L. Wollam, W. Dallas Hall, D. J. Unger, M. B. Douglas, and R. P. Bain, “Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension,” Clinical Pharmacology and Therapeutics, vol. 36, no. 6, pp. 731–737, 1984. View at Google Scholar · View at Scopus
  11. B. Dahlöf and L. Hansson, “The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide,” Journal of Internal Medicine, vol. 234, no. 3, pp. 271–279, 1993. View at Google Scholar · View at Scopus
  12. J. R. Petersen, H. Drabaek, G. Gleerup, J. Mehlsen, L. J. Petersen, and K. Winther, “ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension,” Angiology, vol. 47, no. 3, pp. 233–240, 1996. View at Google Scholar · View at Scopus
  13. K. Landmark, M. Forsman, K. Lindberg et al., “Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters,” Journal of Human Hypertension, vol. 9, no. 4, pp. 281–285, 1995. View at Google Scholar · View at Scopus
  14. J. E. Otterstad, G. Froeland, A. K. W. Soeyland, K. M. Knutsen, and T. Ekeli, “Changes in left ventricular dimensions and systolic function in 100 mildly hypertensive men during one year's treatment with atenolol versus hydrochlorothiazide and amiloride (moduretic): a double-blind, randomized study,” Journal of Internal Medicine, vol. 231, no. 5, pp. 493–501, 1992. View at Google Scholar · View at Scopus
  15. R. Fagard, A. Amery, T. Reybrouck, P. Lunen, and L. Billiet, “Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients,” American Journal of Cardiology, vol. 46, no. 2, pp. 295–300, 1980. View at Google Scholar · View at Scopus
  16. F. M. Fouad, R. C. Tarazi, E. L. Bravo, and S. C. Textor, “Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril),” Hypertension, vol. 6, no. 2, pp. 167–174, 1984. View at Google Scholar · View at Scopus
  17. G. E. Garavaglia, F. H. Messerli, B. D. Nunez, R. E. Schmieder, and E. D. Frohlich, “Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension,” American Journal of Cardiology, vol. 62, no. 13, pp. 912–916, 1988. View at Google Scholar · View at Scopus
  18. E. Grossman, F. H. Messerli, S. Oren, F. Soria, and R. E. Schmieder, “Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy,” American Journal of Cardiology, vol. 72, no. 7, pp. 574–579, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. R. K. Gupta, S. E. Kjeldsen, L. Krause et al., “Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor,” Clinical Pharmacology and Therapeutics, vol. 48, no. 1, pp. 41–49, 1990. View at Google Scholar · View at Scopus
  20. P. Lund-Johansen and P. Omvik, “Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension,” Journal of Hypertension—Supplement, vol. 2, no. 2, pp. S49–S56, 1984. View at Google Scholar · View at Scopus
  21. S. Oren, F. H. Messerli, E. Grossman, G. E. Garavaglia, and E. D. Frohlich, “Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension,” Journal of the American College of Cardiology, vol. 17, no. 5, pp. 1183–1187, 1991. View at Google Scholar · View at Scopus
  22. B. Ricciardelli, M. Volpe, B. Trimarco et al., “Haemodynamic and clinical effects of long-term treatment of essential hypertension with captopril,” European Heart Journal, vol. 4, no. 7, pp. 496–501, 1983. View at Google Scholar · View at Scopus
  23. D. E. Uehlinger, C. P. Ferrier, R. Matthieu et al., “Antihypertensive contribution of sodium depletion and the sympathetic axis during chronic angiotensin II converting enzyme inhibition,” Journal of Hypertension, vol. 7, no. 11, pp. 901–907, 1989. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Valvo, L. Gammaro, V. Bedogna et al., “Systemic and renal hemodynamic changes after two-month treatment with enalapril in patients with essential hypertension,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 25, no. 12, pp. 656–659, 1987. View at Google Scholar · View at Scopus
  25. E. Valvo, P. Casagrande, V. Bedogna et al., “Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension,” Journal of Hypertension, vol. 8, no. 11, pp. 991–995, 1990. View at Publisher · View at Google Scholar · View at Scopus
  26. R. M. Zusman, D. M. Christensen, J. Higgins, and C. A. Boucher, “Effects of fosinopril on cardiac function in patients with hypertension. Radionuclide assessment of left ventricular systolic and diastolic performance,” American Journal of Hypertension, vol. 5, no. 4 I, pp. 219–223, 1992. View at Google Scholar · View at Scopus
  27. G. G. Rogers, C. Rosendorff, C. Goodman, and H. M. Radford, “Effects of angiotensin converting enzyme inhibition and β-blockade on exercise responses in hypertensive patients,” Journal of Hypertension, vol. 6, no. 4, pp. S662–S665, 1988. View at Google Scholar · View at Scopus
  28. I. C. Haznedaroglu, Y. Erdem, L. Tokgözoglu et al., “Effects of ace inhibition on left ventricular dimensions and haemodynamics in systemic hypertension: a radionuclide and echocardiographic study,” Central African Journal of Medicine, vol. 41, no. 4, pp. 118–123, 1995. View at Google Scholar · View at Scopus
  29. J. Soma, S. Aakhus, K. Dahl, T. E. Widerøe, and T. Skjærpe, “Total arterial compliance in ambulatory hypertension during selective β1-adrenergic receptor blockade and angiotensin-converting enzyme inhibition,” Journal of Cardiovascular Pharmacology, vol. 33, no. 2, pp. 273–279, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. R. M. Zusman, D. M. Christensen, J. Higgins, and C. A. Boucher, “Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications,” Journal of Cardiovascular Pharmacology, vol. 20, no. 2, pp. 216–222, 1992. View at Google Scholar · View at Scopus
  31. O. K. Andersson, B. Persson, B. R. Widgren, and M. Wysocki, “Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist,” Journal of Cardiovascular Pharmacology, vol. 15, supplement 1, pp. S87–S89, 1990. View at Google Scholar · View at Scopus
  32. N. E. Bruun, H. Ibsen, F. Nielsen, M. D. Nielsen, A. G. Mølbak, and O. J. Hartling, “The influence of nifedipine treatment on counter-regulatory mechanisms in essential hypertension,” Journal of Hypertension, vol. 3, no. 3, pp. S223–S225, 1985. View at Google Scholar · View at Scopus
  33. F. M. Fouad, R. Pedrinelli, and E. L. Bravo, “Clinical and systemic hemodynamic effects of nitrendipine,” Clinical Pharmacology and Therapeutics, vol. 35, no. 6, pp. 768–775, 1984. View at Google Scholar · View at Scopus
  34. E. D. Frohlich, M. J. McLoughlin, C. J. Losem, R. Ketelhut, and F. H. Messerli, “Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension,” American Journal of Cardiology, vol. 68, no. 13, pp. 1346–1350, 1991. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Grossman, S. Oren, G. E. Garavaglia, F. H. Messerli, and E. D. Frohlich, “Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension,” Circulation, vol. 78, no. 6, pp. 1394–1400, 1988. View at Google Scholar · View at Scopus
  36. E. Grossman, F. H. Messerli, S. Oren, B. Nunez, and G. E. Garavaglia, “Cardiovascular effects of isradipine in essential hypertension,” American Journal of Cardiology, vol. 68, no. 1, pp. 65–70, 1991. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Lund-Johansen, P. Omvik, W. White et al., “Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension,” Journal of Hypertension, vol. 8, no. 12, pp. 1129–1136, 1990. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Lund-Johansen and P. Omvik, “Chronic hemodynamic effects of tiapamil and felodipine in essential hypertension at rest and during exercise,” Journal of Cardiovascular Pharmacology, vol. 15, supplement 4, pp. S42–S47, 1990. View at Google Scholar · View at Scopus
  39. C. Marone, S. Luisoli, and F. Bomio, “Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine,” Kidney International, vol. 28, no. 4, pp. 658–665, 1985. View at Google Scholar · View at Scopus
  40. C. Mazzola, C. Borgnino, D. Colombo et al., “Antihypertensive and hemodynamic effects of slow-release nicardipine,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 26, no. 10, pp. 503–508, 1988. View at Google Scholar · View at Scopus
  41. S. Oren, E. Gossman, and E. D. Frohlich, “Effects of calcium entry blockers on distribution of blood volume,” American Journal of Hypertension, vol. 9, no. 7, pp. 628–632, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. R. E. Schmieder, F. H. Messerli, G. E. Garavaglia, and B. D. Nunez, “Cardiovascular effects of verapamil in patients with essential hypertension,” Circulation, vol. 75, no. 5, pp. 1030–1036, 1987. View at Google Scholar · View at Scopus
  43. D. B. Toftdahl and G. S. Andersen, “Effect of long-term nifedipine treatment on body fluid composition in essential hypertension,” Journal of Human Hypertension, vol. 3, no. 3, pp. 203–206, 1989. View at Google Scholar · View at Scopus
  44. T. C. K. Tham, N. Herity, S. Guy, and B. Silke, “Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope,” British Journal of Clinical Pharmacology, vol. 36, no. 6, pp. 555–560, 1993. View at Google Scholar · View at Scopus
  45. C. V. S. Ram, D. G. Gonzalez, W. Featherston, C. Lugo, J. Ralakis, and N. M. Kaplan, “Nicardipine and propranolol in the treatment of hypertension: similar antihypertensive but dissimilar hemodynamic actions,” American Heart Journal, vol. 119, no. 2, pp. 463–467, 1990. View at Google Scholar · View at Scopus
  46. V. Vulpis, T. M. Seccia, S. Ricci, M. D. Lograno, E. Daniele, and A. Pirrelli, “Non-invasive haemodynamic study in hypertensive subjects after treatment with verapamil slow release,” Pharmacological Research, vol. 30, no. 2, pp. 153–160, 1994. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Amery, L. Billiet, A. Boel, R. Fagard, T. Reybrouck, and J. Willems, “Mechanism of hypotensive effect during beta adrenergic blockade in hypertensive patients. Hemodynamic and renin response to a new cardioselective agent: Tenormin or ICI 66,082,” American Heart Journal, vol. 91, no. 5, pp. 634–642, 1976. View at Google Scholar · View at Scopus
  48. G. S. Andersen, O. J. Hartling, H. O. Hein, and A. Leth, “Changes in blood pressure, fluid volumes and glomerular filtration rate during long-term treatment with prizidilol, an antihypertensive drug with combined vasodilatator and β-adrenoceptor blocking actions,” Danish Medical Bulletin, vol. 32, no. 5, pp. 280–283, 1985. View at Google Scholar · View at Scopus
  49. N. de Luca, B. Ricciardelli, G. Groothold, A. Cuocolo, M. Volpe, and B. Trimarco, “Changes in left ventricular anatomy and systemic hemodynamics induced by antihypertensive therapy with indenolol,” Journal of clinical hypertension, vol. 3, no. 2, pp. 125–134, 1987. View at Google Scholar · View at Scopus
  50. G. R. Dreslinski, F. H. Messerli, F. G. Dunn, D. H. Suarez, E. Reisin, and E. D. Frohlich, “Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension,” Circulation, vol. 65, no. 7, pp. 1365–1368, 1982. View at Google Scholar · View at Scopus
  51. A. G. Dupont, P. Vanderniepen, A. M. Bossuyt, M. H. Jonckheer, and R. O. Six, “Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function,” British Journal of Clinical Pharmacology, vol. 20, no. 2, pp. 93–99, 1985. View at Google Scholar · View at Scopus
  52. R. C. Edwards and E. B. Raftery, “Haemodynamic effects of long term oral labetalol,” British Journal of Clinical Pharmacology, vol. 3, no. 4, supplement 3, pp. 733S–736S, 1976. View at Google Scholar · View at Scopus
  53. M. C. Fahrenbach, S. M. Yurgalevitch, J. M. Zmuda, and P. D. Thompson, “Effect of doxazosin or atenolol on exercise performance in physically active, hypertensive men,” American Journal of Cardiology, vol. 75, no. 4, pp. 258–263, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Fariello, C. L. Alicandri, E. Agabiti-Rosei et al., “Effects of prizidilol (SKF 92657) on blood pressure, haemodynamics, sympathetic nervous system activity and plasma volume in essential hypertension,” Clinical Science, vol. 61, supplement 7, pp. 465s–468s, 1981. View at Google Scholar · View at Scopus
  55. P. Fitscha, W. Meisner, G. Brandstetter, and B. Tiso, “Haemodynamic effects of short-term treatment with bopindolol in essential hypertension,” European Journal of Clinical Pharmacology, vol. 34, no. 4, pp. 411–413, 1988. View at Google Scholar · View at Scopus
  56. E. D. Frohlich, F. H. Messerli, G. R. Deslinski, and I. Kobrin, “Long-term renal hemodynamic effects of nadolol in patients with essential hypertension,” American Heart Journal, vol. 108, no. 4, pp. 1141–1143, 1984. View at Google Scholar · View at Scopus
  57. M. Frisk Holmberg, L. Jorfeldt, and A. Juhlin-Dannfeldt, “Influence of alprenolol on hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension,” Clinical Pharmacology and Therapeutics, vol. 21, no. 6, pp. 675–684, 1977. View at Google Scholar · View at Scopus
  58. M. Frisk-Holmberg, A. Juhlin-Dannfelt, and H. Aström, “Haemodynamic and metabolic responses to prolonged exercise after chronic β1-adrenoceptor blockade in hypertensive man,” Clinical Physiology, vol. 5, no. 3, pp. 231–242, 1985. View at Google Scholar · View at Scopus
  59. S. N. Hunyor, G. E. Bauer, M. Ross, and H. Larkin, “Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects,” Australian and New Zealand Journal of Medicine, vol. 10, no. 2, pp. 162–166, 1980. View at Google Scholar · View at Scopus
  60. M. Leeman, P. van de Borne, F. Collart et al., “Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure,” Journal of Cardiovascular Pharmacology, vol. 22, no. 6, pp. 785–791, 1993. View at Google Scholar · View at Scopus
  61. P. Lund-Johansen, “Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol,” European Heart Journal, vol. 4, pp. 1S–12S, 1983. View at Google Scholar · View at Scopus
  62. P. Lund-Johansen and O. M. Bakke, “Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension,” British Journal of Clinical Pharmacology, vol. 7, no. 2, pp. 169–174, 1979. View at Google Scholar · View at Scopus
  63. P. Lund-Johansen and P. Omvik, “Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect,” Cardiovascular Drugs and Therapy, vol. 5, no. 3, pp. 605–616, 1991. View at Google Scholar · View at Scopus
  64. P. Lund-Johansen and O. J. Ohm, “Haemodynamic long term effects of metoprolol at rest and during exercise in essential hypertension,” British Journal of Clinical Pharmacology, vol. 4, no. 2, pp. 147–151, 1977. View at Google Scholar · View at Scopus
  65. P. Lund-Johansen and O. J. Ohm, “Haemodynamic long term effects of β receptor blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol,” Clinical Science and Molecular Medicine, vol. 51, no. 3, pp. 481S–483S, 1976. View at Google Scholar · View at Scopus
  66. P. Lund-Johansen and P. Omvik, “Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise,” Journal of Cardiovascular Pharmacology, vol. 4, no. 6, pp. 1012–1017, 1982. View at Google Scholar · View at Scopus
  67. P. Lund-Johansen and P. Omvik, “Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise,” European Heart Journal, vol. 13, no. 2, pp. 281–286, 1992. View at Google Scholar · View at Scopus
  68. E. Malacco, F. Mailland, E. Bosisio et al., “Acute and long-term haemodynamic effects of propranolol and indenolol in hypertension,” European Journal of Clinical Pharmacology, vol. 30, no. 2, pp. 157–160, 1986. View at Google Scholar · View at Scopus
  69. P. Omvik and P. Lund-Johansen, “The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol,” Cardiovascular Drugs and Therapy, vol. 4, no. 4, pp. 1135–1144, 1990. View at Google Scholar · View at Scopus
  70. L. Poirier, J. Cléroux, A. Nadeau, and Y. Lacourcière, “Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients,” Journal of Hypertension, vol. 19, no. 8, pp. 1429–1435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Rasmussen and P. E. Nielsen, “Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension,” British Journal of Clinical Pharmacology, vol. 12, no. 3, pp. 349–353, 1981. View at Google Scholar · View at Scopus
  72. S. Rasmussen and K. Rasmussen, “Influence of metoprolol, alone and in combination with a thiazide diuretic, on blood pressure, plasma volume, extracellular volume and glomerular filtration rate in essential hypertension,” European Journal of Clinical Pharmacology, vol. 15, no. 5, pp. 305–310, 1979. View at Google Scholar · View at Scopus
  73. B. Trimarco, A. Cuocolo, G. Groothold et al., “Indenolol: a new antihypertensive agent: efficacy, toxicity, and hemodynamic effects in a crossover double-blind study with metoprolol,” Journal of Clinical Pharmacology, vol. 25, no. 5, pp. 328–336, 1985. View at Google Scholar · View at Scopus
  74. K. Weber, T. Bohmeke, R. van der Does, and S. H. Taylor, “Hemodynamic differences between metoprolol and carvedilol in hypertensive patients,” American Journal of Hypertension, vol. 11, no. 5, pp. 614–617, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Wikstrand, B. Trimarco, G. Buzzetti et al., “Increased cardiac output and lowered peripheral resistance during metoprolol treatment,” Acta Medica Scandinavica, vol. 214, no. 672, pp. 105–110, 1983. View at Google Scholar · View at Scopus
  76. M. Galderisi, A. D'Errico, M. Sidiropulos, P. Innelli, O. de Divitiis, and G. de Simone, “Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension,” Journal of Hypertension, vol. 27, no. 10, pp. 2108–2115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. T. B. Huedo-Medina, J. Sánchez-Meca, F. Marín-Martínez, and J. Botella, “Assessing heterogeneity in meta-analysis: Q statistic or I2 index?” Psychological Methods, vol. 11, no. 2, pp. 193–206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. G. H. Williams, “Converting-enzyme inhibitors in the treatment of hypertension,” The New England Journal of Medicine, vol. 319, no. 23, pp. 1517–1525, 1988. View at Google Scholar · View at Scopus
  79. R. P. Blankfield, “Implications of calculated intravascular volume changes upon atherosclerotic cardiovascular disease,” Clinical Hemorheology and Microcirculation, vol. 38, no. 2, pp. 75–81, 2008. View at Google Scholar · View at Scopus
  80. A. Kumar, R. Anel, E. Bunnell et al., “Preload-independent mechanisms contribute to increased stroke volume following large volume saline infusion in normal volunteers: a prospective interventional study,” Critical Care, vol. 8, no. 3, pp. R128–R136, 2004. View at Google Scholar · View at Scopus
  81. A. Kumar, R. Anel, E. Bunnell et al., “Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers,” Intensive Care Medicine, vol. 30, no. 7, pp. 1361–1369, 2004. View at Google Scholar · View at Scopus
  82. F. Turnbull and Blood Pressure Lowering Treatment Trialists' Collaboration, “Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials,” The Lancet, vol. 362, no. 9395, pp. 1527–1535, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. B. M. Psaty, T. Lumley, C. D. Furberg et al., “Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis,” The Journal of the American Medical Association, vol. 289, no. 19, pp. 2534–2544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Turnbull and Blood Pressure Lowering Treatment Trialists' Collaboration, “Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials,” Archives of Internal Medicine, vol. 165, no. 12, pp. 1410–1419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. R. P. Blankfield, “Calculated effect of fluid retention upon velocity of blood flow and turbulence: implications for atherosclerosis,” Clinical Hemorheology and Microcirculation, vol. 47, no. 2, pp. 79–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. M. E. Ernst and M. Moser, “Drug therapy: use of diuretics in patients with hypertension,” The New England Journal of Medicine, vol. 361, no. 22, pp. 2153–2164, 2009. View at Publisher · View at Google Scholar · View at Scopus